Compare Agilent Technologies Inc (A) vs Mesoblast Limited (MESO) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Agilent Technologies Inc vs Mesoblast Limited — how do they compare? Agilent Technologies Inc trades at $129.02 (market cap $37.04B), while Mesoblast Limited trades at $13.83 (market cap $1.82B). The key difference: Agilent Technologies Inc is far larger — about 20.4× Mesoblast Limited's market cap, and Agilent Technologies Inc pays a 0.78% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals.
| A | MESO | |
|---|---|---|
Market Cap | $37.04B | $1.82B |
Sector | Health | Technology |
52-Week High | $157.20 | $20.96 |
52-Week Low | $110.24 | $10.45 |
Enterprise Value | $38.59B | $1.82B |
Dividend Yield | 0.78% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Agilent Technologies (A) trades at $131.14, up 0.34% on the day, with a bearish technical signal but strong analyst support. The stock shows solid profitability with a net margin of 19.55% and ROE of 21.33%, supported by recent earnings beats. Recent acquisitions like Biocare Medical highlight growth initiatives, while cash flow trends remain positive. Valuation ratios such as P/E of 26.22 are elevated but align with quality growth expectations.
The outlook is positive given analyst consensus with a $154.90 price target and 77.5% buy ratings. Risks include execution of acquisitions and macroeconomic pressures on life sciences spending. The stock offers growth potential from AI-driven product launches, though technical resistance near $132 may cap near-term gains.
MESO trades at $14.33, down 0.35% with a bearish technical signal. The company reported Q1 2025 revenue of $17.20M with a gross margin of 80.52% but significant losses (-$102.14M net income). Recent developments include FDA BLA filing for rexlemestrocel-L in heart failure and a $50M debt facility draw. Analyst consensus shows 45% buy ratings amid high valuation multiples (P/S 30.52).
Outlook hinges on regulatory approvals and commercial execution. The stock offers speculative upside from pipeline catalysts but carries substantial risk from cash burn and clinical trial outcomes. Investors face volatility from binary regulatory events while current fundamentals reflect pre-revenue biotech challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Agilent Technologies Inc
Originally spun out of Hewlett-Packard in 1999, Agilent has evolved into a leading life sciences and diagnostics firm. Today, Agilent's measurement technologies serve a broad base of customers with its three operating segments: life science and applied tools (45% of fiscal 2021 sales), cross lab (35% of sales consisting of consumables and services related to its life science and applied tools), and diagnostics and genomics (20%). Over half of its sales are generated from the biopharmaceutical, chemical, and energy end markets, but it also supports clinical lab, environmental, forensics, food, academic, and government-related organizations. The company is geographically diverse, with operations in the U.S. (34%) and China (20%) representing the largest country concentrations.
Read more on A →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
